India: Drug Patents - A Necessity

Last Updated: 7 May 2003

Authored by Jidesh Kumar M.D., Associate, Intellectual Property Department, Kochhar & Co.

The establishment of Trade-Related Intellectual Property Rights (TRIPS) regime establishes new disciplines for many countries in copyright, trademarks, industrial designs and patents.

Two groups of issues dominate the debate on intellectual property in India - patents for pharmaceuticals and agricultural chemicals; and the implications of the WTO agreement on products based on local species.

In India, there is one big paradox. The Indian drug industry has been protected from foreign competition for two decades. And yet it is one of the most competitive in the world. Indian drug exports grew by 35% annually over the past decade to reach $1.5 billion in 2001.

The Beginning

In December 1997, the Appellate Body which handles appeals in disputes between WTO members, upheld a panel ruling that India was violating its obligations on pharmaceutical and agricultural chemicals patents.

Broadly speaking, the issue was a technicality concerning the transition to full patent protection, although it does have serious implications. But behind it lies an intense debate within India, not least within the Indian drug industry itself.

Patent protection for pharmaceuticals raises the following distinct issues:

1. What are the impacts for public health? Some say patenting drugs raises costs, puts them out of the reach of the poor (in this case most of the country), and therefore damages public health. Others counter that it encourages the introduction of new drugs, either by directly encouraging invention in the country (in India) or through newly invented imports that are protected, or through foreign investment in production (and possibly research) in India. (India’s size might make this a more attractive prospect than investing in a smaller country.)

2. What are the impacts for Indian manufacturing and the Indian economy? The small players, which have been making copies, fear that they will not have sufficient capital or technology to invent new drugs that can be patented. As a result, they feel the market will be polarized in favour of foreign multinationals. The larger firms on the other hand, are in full support of patents which they hope will attract foreign investment and thereby stimulate joint ventures and research.

With full implementation still a couple of years away, concrete evidence to support either side is not yet available. But there is already plenty to think about.

While the government has implemented the agreement though it has faced resistance from local drug manufacturers and consumers.

The Indian Drug Manufacturers Association (IDMA) protested in 1994 that prices of drugs shall go up by 5 to 20 times as a consequence of accepting the TRIPS [Trade-Related Aspects of Intellectual Property Rights] proposals. However, the government claimed that once the crutches of weak patent law are removed, we can successfully negotiate with research-based international companies to boost export earnings, create more employment and benefit from the transfer of technology".

The government had some reservations about the TRIPS Agreement. But it signed the deal, taking the view that the package of agreements in all areas of trade — the result of the 1986-94 Uruguay round of negotiations — was on balance in India’s interests.

The crux of the matter is that when the world is moving in one direction, it makes no sense for India to move in the opposite direction. At best, India can seek amelioration, which it has done successfully. This is not happening overnight. As a developing country, India has a 10-year transitional period (until 2005) for giving full patent protection for pharmaceutical and agro-chemical products. These provisions are designed to allow India and other developing countries time to adjust.

Protecting the baby

In the post-independence era, over 90% of the Indian pharmaceutical industry’s market share and ownership was dominated by foreign companies. This made the country increasingly dependent on imports for bulk drugs and formulations. As a result, drug prices were amongst the highest in the world.

In 1970, the government took two important steps to break the multinational domination and foster a self-reliant indigenous industry. It introduced a Drug Price Control Order (DPCO) to protect consumers against high prices. Ceilings were set on the retail prices of essential drugs and those required to treat common diseases. In an attempt to stimulate domestic industry, new drugs manufactured through indigenous technology were exempt from price controls for five years.

A far more significant reform was the Indian Patent Act of 1970, which recognised process patents (patenting the process used to make a particular drug formulation), but not product patents (patenting the product itself). These reforms made new drugs available cheaply and promoted import substitution by encouraging local firms to make copies of the drugs by developing their own processes, followed by bulk drug production. The Patent Act effectively served to legalise "copying" of drugs that were patentable in developed countries as newly invented products, but were unprotected in India. Exempt from paying for licences and royalties, Indian companies could now access the newest molecules from all over the world and reformulate them for sale in the domestic market. The limited patent protection for product processes was valid for seven years, which meant by the time an application for patent protection was processed, the duration of protection was almost over.

Moreover, high tariffs at 80% encouraged Indian firms to develop a manufacturing base from the basic stages and produce cost efficient bulk drugs (raw materials) and formulations (finished product). As a result, the Indian market accounts for US$4.3bn annually, shared among 16,000 licensed drug companies.

The pendulum has swung towards domestic production that meets 70% of the bulk drug requirements and 90% of its formulations. Today in mid 2003, Indian companies enjoy market shares of 70% for domestic formulations and 85% for bulk drugs. The reversal of fortunes in the pharmaceutical industry has created a dominant position for local firms. Many of the foreign multinationals have slowly opted out of the Indian market, as a result of the disadvantages they face, compared to their local rivals. Other restrictions such as price controls served as a further disincentive to invest in the Indian market.

The fear: increase in prices

Indians fear that costs of medicines will rise as a result of royalty payments and increased prices for products manufactured under license. Local companies could face foreign competition. After India ratified the WTO agreements, the press accused the government of selling out to rapacious multinationals and making Indian patients pay for the sell out"

However, recent evidence suggests that these gloomy predictions are largely unfounded. India has been granted breathing space in the form of a 10-year transitional period before it is obliged to enforce patent protection for drugs. However, developing countries that do not provide patent protection for pharmaceuticals and agricultural chemicals still have to do two things. They have to set up a mechanism (known informally as a "mailbox") that allows inventions to be notified to the patent authorities — this is a way of establishing that the invention is "new", an important criterion for granting a patent once the system for patent protection is eventually set up. And if the country allows the new drug to be marketed, the right has to be given exclusively for a period to the company that invented it. India has already implemented this in its Patents Act by an amendment in 2002.

One recent estimate suggests that only 15% of the Indian drug market will be covered by patents after 2005 and be subjected to price premiums as a result. The remaining 85% of the market will continue to be exposed to "the full impact of generic [i.e. non-brand name drugs] competition, to which patented products will themselves ultimately contribute when their patents expire". Moreover, as the TRIPS Agreement does not allow for backdating, drugs already in the market will be exempt from patenting.

What the market will bear

Will drug prices rise dramatically? On the one hand, there are several checks and balances within the Indian drug market that could prevent this from happening, such as India’s low purchasing power, the government’s price control mechanism and competition in the drug market itself.

Whilst India comprises 16% of the world’s population, it accounts for a mere 1% of global healthcare spending. Its per capita consumption of drugs amounts to less than US $ 6 per annum, compared to US $ 414 in the US. India’s domestic healthcare system only covers 3.7% of its population of over 980m. Therefore 75% of expenditure on medicines is borne privately by patients. Given these circumstances and the low per capita incomes, prices have to be maintained at an affordable level. If they exceed the threshold of affordability, the government price control mechanism will keep prices in check. In other words the self-paying Indian pharmaceutical market will in effect be self-regulating in terms of drug pricing, without the need for government intervention.

Moreover, competition amongst multiple producers of the same drug has resulted in lowering the price of drugs in India, to the extent that they are now amongst the cheapest in the world. Drugs outside the price control mechanism have experienced a particularly dramatic fall in prices, owing to competition. Industrialists also predict that competition between firms will continue to act as a safeguard against price escalations resulting from patent protection.

Other forces

On the other hand, there are other pressures that could indeed cause prices to rise. One, ironically, is the government’s new drug pricing policy. In a bid to attract foreign investment, the government has ended laws that used to discriminate against multinationals, including some price controls. It is argued that the decontrolling will in itself lead to a hike in drug prices, irrespective of whether a new intellectual property regime is introduced.

This has created a major dilemma for the government. Deregulation and patent protection are considered necessary encouragements for research and development because they allow companies to recover the costs. But their immediate impact could be social upheaval, resulting from an increase in the price of essential drugs; and it is the lifting of price controls that could have a more serious impact on drug consumers.

A boom in generic drugs

For Indian companies, the new policies offer three options: to try to compete with the multinationals by producing their own inventions; to produce patented drugs under licence; or to make drugs that are free from patents, in particular the generics — drugs identified by chemical formulation (such as aspirin) and not by brand name. The prospects for generics in particular look good.

According to a recent study by the Indian Drug Manufacturers Association, within the next 10 years, patents of most of the world’s top 10 drugs will expire. The market for generic drugs will correspondingly increase. The global market for generic drugs is estimated around US$20bn currently and is forecast to rise to US$30bn by 2000. With well-established capabilities in the manufacture of bulk drugs, India can meet the challenge from the ‘hard’ patent regime, by invading Western markets with generic drugs.

End of a copying culture?

In a recent World Bank study, 81% of US research-based pharmaceutical companies complained intellectual property protection is too weak in India to permit licensing of their newest or most effective technology and zero percent would invest in R&D [research and development]. Therefore, strengthened patent protection is expected to encourage foreign direct investment in India. An environment hospitable to foreign innovative technology sets in motion a range of other dynamics such as licensing, co-marketing and joint ventures, generating multiplier effects that benefit local drug manufacturers.

In Malaysia for instance, the level of foreign direct investment increased significantly as a consequence of enforcing the TRIPS Agreement and is currently 11 times the amount India has managed to attract. Patent protection could therefore, improve the quality of medical care in India, as the country progresses from a copying culture, to one that induces local innovation. However, the extent that a new intellectual property regime will have a direct impact in stimulating research and development in India remains open to debate.

The case of Japan provides an insight into ways in which India’s research and development industry can profit from TRIPS. In 1970, Japan was in a similar situation as India today. As a result of introducing patent protection, research and development expenditure amongst top Japanese drug firms rose from 6% of sales in 1975, to 18.8% in 1999. During the same period, their net profit margins rose from 3.6% of sales to 8.7%. In the 20 years preceding the new patent legislation, Japanese companies introduced 4 new major global drugs. By contrast, during the 10 years following the introduction of patent protection, Japanese drug companies introduced 25 new major global drugs into the market. Foreign investment in Japan also rose dramatically during the new patent regime.

The Japanese case suggests that product patents are a prerequisite to achieving a successful transformation from a copying and parasitic culture, to one of indigenous design and innovation. But the question is does India have the capital and level of technology that Japan had to invest in research and development?

Perhaps India’s ongoing liberalization programme has stimulated the process by encouraging further foreign direct investment and capital accumulation in the burgeoning private sector which can be channelled into research and development projects.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
In association with
Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions